What is Hinge Bio?
Hinge Bio is a pioneering biotechnology firm dedicated to advancing the next generation of therapeutics through its revolutionary GEM-DIMER platform. By engineering antibodies with enhanced activity and unprecedented degrees of multivalency and multispecificity, the company addresses critical gaps in disease treatment. This technological edge allows for superior safety and efficacy profiles compared to traditional therapeutic modalities. Currently, the organization is focused on scaling its operations, expanding its senior management team, and presenting robust preclinical data to validate its drug development pipeline. As a key player in the life sciences ecosystem, Hinge Bio is strategically positioned to redefine how complex diseases are managed at the molecular level.
How much funding has Hinge Bio raised?
Hinge Bio has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2025): $30M with participation from InVivium Capital, Point72, Lightswitch Capital, and Ridgeback Capital
Key Investors in Hinge Bio
InVivium Capital
InVivium Capital is a venture capital fund that specializes in investing in transformative life sciences and healthcare innovations.
Point72
Point72 is a private investment management firm that manages a number of private investment funds in long-short equity and quantitative equities.
Lightswitch Capital
Lightswitch Capital is dedicated to empowering entrepreneurs by investing in and partnering with private healthcare companies to foster long-term growth.
What's next for Hinge Bio?
Looking ahead, Hinge Bio is poised to utilize its recent capital infusion to drive its GEM-DIMER programs through the rigorous demands of clinical trials. The company's strategic roadmap includes the continued recruitment of top-tier scientific talent and the expansion of its internal research capabilities. By maintaining a focus on high-impact drug development, Hinge Bio intends to translate its preclinical successes into tangible patient outcomes. Investors and industry observers will be closely monitoring the firm's progress as it navigates the transition from a research-focused entity to a clinical-stage developer, with a clear objective of delivering transformative medicines to market.
See full Hinge Bio company page
